​

Crinetics Pharmaceuticals (CRNX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRNX Stock Forecast

Crinetics Pharmaceuticals (CRNX) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $75.50, with a high of $91.00 and a low of $60.00. This represents a 148.19% increase from the last price of $30.42.

$30 $43 $56 $69 $82 $95 High: $91 Avg: $75.5 Low: $60 Last Closed Price: $30.42

CRNX Stock Rating

Crinetics Pharmaceuticals stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 15 Strong Sell Sell Hold Buy Strong Buy

CRNX Price Target Upside V Benchmarks

TypeNameUpside
StockCrinetics Pharmaceuticals148.19%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts127
Avg Price Target$60.00$75.50$74.71
Last Closing Price$30.42$30.42$30.42
Upside/Downside97.24%148.19%145.60%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 255101--16
Mar, 255101--16
Feb, 2559---14
Jan, 25591--15
Dec, 24581--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 24, 2025Alex ThompsonStifel Nicolaus$60.00$35.9466.94%97.24%
Feb 28, 2025JMP Securities$91.00$35.78154.33%199.15%
Aug 09, 2024Douglas TsaoH.C. Wainwright$69.00$50.7435.99%126.82%
Jun 04, 2024Leland GershellOppenheimer$74.00$46.2859.90%143.26%
May 23, 2024Brian SkorneyRobert W. Baird$62.00$49.1326.20%103.81%
May 22, 2024Jeffrey HungMorgan Stanley$70.00$50.5438.50%130.11%
May 07, 2024Yasmeen RahimiPiper Sandler$97.00$47.47104.34%218.87%
Mar 20, 2024Jonathan WollebenJMP Securities$80.00$45.4975.86%162.98%
Mar 13, 2024Leland GershellOppenheimer$54.00$40.5033.33%77.51%
Aug 31, 2023Leland GershellOppenheimer$40.00$17.43129.49%31.49%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 04, 2025Wolfe ResearchPeer Performinitialise
Sep 27, 2024OppenheimerUnderperformUnderperformhold
Sep 27, 2024Piper SandlerOverweightOverweighthold
Aug 09, 2024H.C. WainwrightBuyBuyhold
Jul 02, 2024Piper SandlerOverweightOverweighthold
Jun 28, 2024OppenheimerUnderperformUnderperformhold
Jun 04, 2024OppenheimerUnderperformUnderperformhold
Jun 04, 2024Piper SandlerOverweightOverweighthold
Jun 04, 2024OppenheimerOutperformOutperformhold
May 23, 2024Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.39$-3.08$-3.69$-3.69----
Avg Forecast$-2.35$-3.16$-3.63$-3.69$-3.87$-4.23$-3.16$-0.51
High Forecast$-0.05$-0.90$-3.54$-3.57$-3.35$-2.28$-1.92$-0.13
Low Forecast$-10.97$-11.13$-3.78$-3.94$-5.00$-5.65$-4.38$-1.72
Surprise %1.70%-2.53%1.65%-----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$71.00K$4.74M$4.01M$1.04M----
Avg Forecast$85.50K$4.26M$4.23M$1.60M$6.42M$48.29M$209.55M$519.02M
High Forecast$326.60K$12.51M$4.93M$2.35M$16.81M$48.29M$594.86M$1.47B
Low Forecast$21.07K$1.91M$3.93M$1.41M$2.54M$48.29M$89.73M$222.24M
Surprise %-16.96%11.21%-5.12%-34.91%----

Net Income Forecast

$-650M $-520M $-390M $-260M $-130M $0 Dec 20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-72.86M$-159.95M$-214.53M$-298.41M----
Avg Forecast$-136.58M$-183.75M$-214.53M$-218.09M$-242.43M$-230.34M$-182.92M$-29.47M
High Forecast$-2.77M$-52.17M$-205.73M$-207.46M$-194.27M$-132.55M$-111.27M$-7.56M
Low Forecast$-637.27M$-646.59M$-219.56M$-228.72M$-290.60M$-328.12M$-254.58M$-99.92M
Surprise %-46.65%-12.95%-36.83%----

CRNX Forecast FAQ

Is Crinetics Pharmaceuticals stock a buy?

Crinetics Pharmaceuticals stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Crinetics Pharmaceuticals is a favorable investment for most analysts.

What is Crinetics Pharmaceuticals's price target?

Crinetics Pharmaceuticals's price target, set by 15 Wall Street analysts, averages $75.5 over the next 12 months. The price target range spans from $60 at the low end to $91 at the high end, suggesting a potential 148.19% change from the previous closing price of $30.42.

How does Crinetics Pharmaceuticals stock forecast compare to its benchmarks?

Crinetics Pharmaceuticals's stock forecast shows a 148.19% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Crinetics Pharmaceuticals over the past three months?

  • April 2025: 31.25% Strong Buy, 62.50% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 31.25% Strong Buy, 62.50% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 35.71% Strong Buy, 64.29% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Crinetics Pharmaceuticals’s EPS forecast?

Crinetics Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.87, marking a 4.88% increase from the reported $-3.69 in 2024. Estimates for the following years are $-4.23 in 2026, $-3.16 in 2027, and $-0.51 in 2028.

What is Crinetics Pharmaceuticals’s revenue forecast?

Crinetics Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $6.42M, reflecting a 518.24% increase from the reported $1.04M in 2024. The forecast for 2026 is $48.29M, followed by $209.55M for 2027, and $519.02M for 2028.

What is Crinetics Pharmaceuticals’s net income forecast?

Crinetics Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-242M, representing a -18.76% decrease from the reported $-298M in 2024. Projections indicate $-230M in 2026, $-183M in 2027, and $-29.471M in 2028.